# Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Biopharma Company with 34% Upside Potential

- Link: https://www.directorstalkinterviews.com/xeris-biopharma-holdings-inc-xers-stock-analysis-a-biopharma-company-with-34-upside-potential/4121257634
- Published: 2026-07-24T10:11:10+01:00
- Author: Madison Wilson

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) stands out in the competitive healthcare
sector, particularly in the drug manufacturing industry focused on specialty and
generic medications. With a market capitalization of $1.45 billion, this Chicago-
based biopharmaceutical company is drawing attention from both investors and analysts
for its promising pipeline of therapies addressing chronic endocrine and neurological
diseases.

Currently trading at $8.41, Xeris Biopharma’s stock is perched near the higher end
of its 52-week range of $5.00 to $9.90. This reflects a stable performance in the
market, despite its recent minimal price change. Analysts are notably optimistic
about XERS, with an average target price of $11.29, which suggests a potential upside
of 34.19%. Such prospects are bolstered by the company’s strong revenue growth and
robust product lineup.

Xeris Biopharma’s portfolio includes Gvoke, a ready-to-use liquid-stable glucagon
for severe hypoglycemia, Keveyis for variants of primary periodic paralysis, and
Recorlev, a cortisol synthesis inhibitor for Cushing’s syndrome. Moreover, their
innovative XP-8121, a once-weekly subcutaneous injection for hypothyroidism, is 
progressing through phase 3 clinical trials, promising to expand their therapeutic
offerings.

Despite its lack of a trailing P/E ratio, Xeris Biopharma’s forward P/E of 21.43
indicates potential for future profitability, hinting at favorable financial performance
as its therapies gain market traction. The absence of a PEG ratio and other valuation
metrics can be attributed to its current stage in commercial operations, where reinvestment
into R&D is likely prioritized over near-term profitability.

The company’s financial health is underlined by a free cash flow of approximately
$42.2 million, which provides it with the flexibility to invest in its pipeline 
and expand its market reach. However, the lack of dividend yield and a payout ratio
of 0% suggests that Xeris is channeling its resources into growth and development
rather than immediate shareholder returns.

Analyst sentiment toward Xeris Biopharma is predominantly positive, with six buy
ratings and only one hold rating. This confidence is likely driven by the company’s
innovative products and the strategic development of its pipeline, which align well
with the industry’s growth trends.

Technically, XERS is in bullish territory with its 50-day and 200-day moving averages
at $7.21 and $7.08, respectively. However, the Relative Strength Index (RSI) at 
87.28 indicates the stock is currently overbought, suggesting that investors might
want to watch for potential pullbacks or corrections in the short term.

For individual investors, Xeris Biopharma represents a compelling opportunity within
the biopharma space, combining robust revenue growth potential with an enticing 
upside as the company continues to advance its innovative therapies through clinical
trials and into the market. As always, potential investors should consider the inherent
risks associated with biopharmaceutical companies, including clinical trial outcomes
and regulatory approvals, when making investment decisions.

Share on:
